MKI67 and breast cancer: In breast cancer, an immunolocalization study identified NRF2 as an independent adverse prognostic factor for both recurrence and disease-free survival of patients, and its expression level was significantly associated with the histological grade, Ki-67 labelling index, p62 immunoreactivity, and NAD(P)H: NQO1 level [263].